These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1117 related items for PubMed ID: 23063375

  • 21. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
    Jung J, Choi S, Cho SH, Ghim JL, Hwang A, Kim U, Kim BS, Koguchi A, Miyoshi S, Okabe H, Bae KS, Lim HS.
    Clin Ther; 2010 Jun; 32(6):1178-87. PubMed ID: 20637970
    [Abstract] [Full Text] [Related]

  • 22. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects.
    Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, Stockis A.
    Clin Ther; 2006 May; 28(5):734-44. PubMed ID: 16861095
    [Abstract] [Full Text] [Related]

  • 23. A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers.
    Darwish M, Chang S, Hellriegel ET.
    Clin Ther; 2009 Jan; 31(1):108-14. PubMed ID: 19243711
    [Abstract] [Full Text] [Related]

  • 24. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M, Tempero K, Kirby M, Thompson J.
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
    Kim BH, Shin KH, Kim J, Lim KS, Kim KP, Kim JR, Cho JY, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
    [Abstract] [Full Text] [Related]

  • 26. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
    Malik M, van Gelderen EM, Lee JH, Kowalski DL, Yen M, Goldwater R, Mujais SK, Schaddelee MP, de Koning P, Kaibara A, Moy SS, Keirns JJ.
    Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.
    Groen-Wijnberg M, van Dijk J, Krauwinkel W, Kerbusch V, Meijer J, Tretter R, Zhang W, van Gelderen M.
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):417-429. PubMed ID: 27350625
    [Abstract] [Full Text] [Related]

  • 28. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
    Darwish M, Hellriegel ET.
    Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
    [Abstract] [Full Text] [Related]

  • 29. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G, Angeles-Moreno AP, Contreras-Zavala L, Morales-Martínez M, Rivera-Espinosa L.
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [Abstract] [Full Text] [Related]

  • 30. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
    Musson DG, Kramer WG, Foehr ED, Bieberdorf FA, Hornfeldt CS, Kim SS, Dorenbaum A.
    Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
    [Abstract] [Full Text] [Related]

  • 31. Comparison of the pharmacokinetics of ticlopidine between administration of a combined fixed-dose tablet formulation of ticlopidine 250 mg/ginkgo extract 80 mg, and concomitant administration of ticlopidine 250-mg and ginkgo extract 80-mg tablets: an open-label, two-treatment, single-dose, randomized-sequence crossover study in healthy Korean male volunteers.
    Kim TE, Kim BH, Kim J, Kim KP, Yi S, Shin HS, Lee YO, Lee KH, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2009 Oct; 31(10):2249-57. PubMed ID: 19922896
    [Abstract] [Full Text] [Related]

  • 32. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
    Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stölzel M, Martin N, Gunther A, Van Kerrebroeck P.
    Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
    [Abstract] [Full Text] [Related]

  • 33. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
    Abbas R, Hug BA, Leister C, Gaaloul ME, Chalon S, Sonnichsen D.
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics and tolerability of single escalating doses of fampridine sustained-release tablets in patients with multiple sclerosis: a Phase I-II, open-label trial.
    Vollmer T, Henney HR.
    Clin Ther; 2009 Oct; 31(10):2206-14. PubMed ID: 19922891
    [Abstract] [Full Text] [Related]

  • 35. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M, Almeida L, Falcão A, Soares E, Maia J, Nunes T, Soares-da-Silva P.
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [Abstract] [Full Text] [Related]

  • 36. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 37. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.
    Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, Cho JY, Kim DH, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2011 Nov; 33(11):1819-30. PubMed ID: 22047812
    [Abstract] [Full Text] [Related]

  • 38. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, Ridder A.
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
    Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG.
    Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
    [Abstract] [Full Text] [Related]

  • 40. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation.
    Rittig S, Baka-Ostrowska M, Tøndel C, Walle JV, Kjaeer B, Passier P, Bosman B, Stroosma O, Tannenbaum S.
    J Pediatr Urol; 2020 Feb; 16(1):31.e1-31.e10. PubMed ID: 31787582
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.